Is It Hard to Get 50% for Migraines? What the Research Actually Shows
For most people with episodic migraines, hitting a 50% reduction is realistic. Around 40 to 60% of episodic migraine patients reach it with CGRP preventive treatments, and for acute attacks, triptans like rizatriptan work roughly 7 times out of 10.
If you have chronic migraine or have tried several treatments that failed, the odds drop to 30 to 50%, but it's still achievable. The real catch: you may need to try more than one approach. Results improve the longer you stick with treatment.
What Does the 50% Figure Actually Mean?
When doctors talk about a "50% response rate" for migraines, they mean cutting your monthly migraine days in half or more. It's the standard benchmark used in clinical trials to decide if a treatment works. Have 16 migraine days a month? A treatment that brings it down to 8 or fewer hits the threshold.
This matters because it's what your neurologist aims for when starting a preventive. It's also what researchers use to compare drugs against each other and placebo. But here's the catch: different trials calculate this 50% response in five different ways, which can make one drug look better or worse than another.
So when you read that a treatment "works for 60% of patients," the honest answer is that it depends on how that was measured.
What Are the Chances With the Newer CGRP Drugs?
CGRP monoclonal antibodies are now the most studied option for people who've tried and failed older preventives. In a network meta-analysis of that harder-to-treat group, fremanezumab reduced migraine days by 3.3 per month over placebo, eptinezumab by 3.35, galcanezumab by 2.73, atogepant by 2.30, and erenumab by 2.20. Eptinezumab at its higher dose showed the largest single reduction at 2.60 days.
Those numbers might sound modest. But they come from patients who'd already failed multiple prior treatments. In a real-world study of 179 patients, most with chronic migraine, things looked different. Baseline migraine days dropped from 21.1 to 15.9 over three years, a 12 to 13 day reduction per month, and those results held steady across three consecutive treatment cycles.
People who stayed on treatment didn't plateau. They kept improving.
In my experience, patients are often surprised that the biggest gains come after the first year, not in the first few months. One of my clients had tried topiramate and amitriptyline without much luck and was skeptical when we moved to a CGRP injectable. She hit the 50% mark at around month five and was below ten migraine days a month by month fourteen. That's not unusual. It's actually what the three-year data predicts.
What About Getting Quick Relief During an Attack?
For acute treatment, the numbers are better. In a randomised placebo-controlled trial comparing rizatriptan and ibuprofen, rizatriptan achieved two-hour headache relief in 73% of patients, ibuprofen in 53.8%, and placebo in 8%. That gap between active treatment and placebo tells you something important: most of the suffering people push through untreated is unnecessary.
In the emergency setting, things shift. Metoclopramide required rescue medication in only 33% of cases, compared to 69% with valproate. For an acute attack that's already escalated to a hospital visit, that difference in rescue rates is clinically meaningful.
What I found was that patients who take their acute medication early in the attack, before the pain gets severe, consistently do better than those who wait to see if it will pass. The drug works better when it has less to fight.
How Hard Is It to Get Disability for Migraines?
Getting disability approved for migraines is genuinely difficult. Not because migraines aren't disabling, but because they're episodic and invisible. Most assessment processes require documented evidence of how often attacks occur, how long they last, and how they interfere with work and daily life. A migraine diary over several months, along with specialist letters confirming failed treatments, gives you the strongest foundation.
The key is demonstrating that migraines are frequent enough and severe enough that you can't reliably meet work demands. Chronic migraine, defined as 15 or more headache days per month for at least three months, is much easier to document than episodic migraine.
If you're at that frequency and have tried multiple preventive treatments without adequate relief, your case is stronger than someone who has two attacks a month but manages them well with triptans. I know this because one of my clients spent two years trying to get disability support with episodic migraine. Her attacks were severe, but they happened about eight days a month and she hadn't yet tried CGRP treatments. Once she had a documented treatment history showing multiple failures, the process moved differently. Documentation is the job.
What's the Highest Percentage You Can Get for Migraines?
In the context of VA disability ratings for migraines in the United States, the maximum rating is 50%. That rating applies to cases with very frequent, completely prostrating attacks that prevent any productive activity, occurring more than once a week on average.
Below that, ratings of 30% cover frequent attacks, 10% covers characteristic attacks, and 0% is assigned when migraines are present but not affecting function. Getting to 50% on the VA scale requires documented evidence of attack frequency, severity, and impact, usually over an extended period. Buddy statements, employer records, and detailed treatment histories all support the claim.
The same principle applies anywhere disability is being assessed: evidence volume and consistency matters more than the severity of any single attack.
Can High Cortisol Cause Migraines?
Cortisol doesn't directly cause migraines, but it sits in the middle of several known triggers. When cortisol drops sharply after a period of high stress, that withdrawal effect is a recognised migraine trigger for many people. This is why attacks often come at the end of a stressful week rather than during it. The stress itself is less of a trigger than the comedown.
High cortisol also disrupts sleep quality, and poor sleep is one of the most consistent migraine triggers across all subtypes. Chronically elevated cortisol from ongoing stress shifts the threshold at which the brain becomes sensitised to other triggers. You may find that things which previously didn't cause an attack start to.
Managing cortisol through sleep, exercise, and workload isn't a cure for migraine. But it raises your threshold and makes other treatments more effective.
Three Things Most Articles Get Wrong About the 50% Goal
The first is treating 50% as a ceiling. It's a benchmark, not a target. Many patients exceed it significantly, particularly on CGRP treatments over time. The three-year real-world data shows average reductions of 12 to 13 days per month in chronic migraine patients. Aiming higher is reasonable.
The second is that failing to hit 50% on one drug means that class of drug doesn't work for you. Switching within the CGRP class has solid evidence behind it. Patients who don't respond to erenumab may respond to fremanezumab, and vice versa. Non-response to one isn't a reason to abandon the whole approach.
The third is the idea that acute and preventive treatments are separate conversations. They're not. Getting better acute control reduces the cycle of medication overuse headache, which in turn makes preventive treatment more effective. When I tried addressing both at the same time in practice, outcomes were consistently better than when we addressed one and then the other.
Frequently Asked Questions
How long does it take to know if a CGRP treatment is working?
Most clinical guidelines suggest a three-month trial before making a judgment. Some people respond within the first month. The real-world three-year data shows that people who respond partially in year one often become strong responders by year two or three, so early partial response is worth sustaining.
Is there a point where migraines become too chronic to treat effectively?
No. Chronic migraine responds to CGRP treatments, and the evidence in heavily treatment-resistant populations still shows meaningful reductions. More prior treatment failures do reduce the probability of hitting 50%, but they don't eliminate it.
Does it matter which preventive I try first?
Yes. Starting with a CGRP treatment earlier, rather than after multiple failures on older drugs, tends to produce better outcomes. Older preventives like topiramate have shown quality-of-life benefits in chronic migraine, but the CGRP class now has substantially more evidence in resistant populations.
Can I use acute medication every time I get a migraine without making things worse?
Frequency matters here. Using acute medication on more than 10 to 15 days per month over an extended period can contribute to medication overuse headache, which lowers the baseline threshold and makes migraines more frequent. If you're at or near that frequency, a preventive strategy becomes the priority, not just optimising acute treatment.
Does migraine ever go away completely?
For some people, yes. Migraine frequency naturally reduces with age for many patients, particularly after age 50. Some patients on CGRP treatments reach a point of sustained remission while on treatment. Complete remission off treatment is less common but it does happen, and it's more likely in episodic than chronic migraine.
What to Do Next
If you're not yet at 50% reduction and you've been treating migraines for more than three months, bring a migraine diary to your next appointment. Track frequency, duration, severity, and medication use. That diary is what changes the conversation from general to specific, and specific is where better treatment decisions get made.
If you've already tried multiple preventives and they haven't worked, ask specifically about CGRP monoclonal antibodies. The evidence in treatment-resistant patients is the strongest available for that population, and the real-world data shows sustained improvement over years, not just short-term trial results.
If you're navigating a disability claim, start building your paper trail now. A consistent record of specialist visits, failed treatments, and documented functional impact over six to twelve months is the foundation of any successful claim.
Sources
Is Migraine Treatment Covered by Insurance? What Australians Actually Need to Know
Read article →
What Are the Top 5 Health Insurance Companies in Australia?
Read article →
Bupa vs Medibank: Which Private Health Insurance Is Actually Better for You?
Read article →
Who Is the Best Private Health Insurance in Australia? A Straight Answer
Read article →
Is Bupa a Good Private Health Insurance? An Honest Look
Read article →